iBio Inc. stock rises Wednesday, outperforms market
Shares of iBio Inc. IBIO rose 5.14% to $3.07 Wednesday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ Composite Index COMP rising 1.28% to 20,009.34 ...
iBio Announces New Investments from Board Members and Officers
SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, ...
Yahoo Finance20d
iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio
SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced the expansion of its cardiometabolic and obesity ...
Benzinga.com20d
Nano-Cap iBio Expands Obesity Program With New Antibody Using In-Licensed Platform
iBio in-licensed IBIO-600 from AstralBio for $750,000 in stock, with potential milestone payments of up to $28 million. IBIO-600 showed potent myostatin inhibition in preclinical studies ...
iBio, AstralBio announce development of antibody inhibiting Activin E
Bio (IBIO) in collaboration with AstralBio announced the development of an antibody that inhibits the function of Activin E, a promising ...
Nasdaq20d
IBio Expands Cardiometabolic And Obesity Program
(RTTNews) - iBio, Inc. (IBIO), a preclinical stage biotechnology company, Thursday said it has in-licensed a long-acting anti-myostatin antibody, IBIO-600 from AstralBio, Inc. iBio has initiated a ...
iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio
SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in ...
CNN4y
iBio, Inc.
iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling ...
Nasdaq15d
iBio, Inc. and AstralBio Collaborate to Develop First Antibody Targeting Activin E for Cardiometabolic Disorders and Obesity
iBio, Inc. has announced a collaboration with AstralBio Inc. to develop an innovative antibody targeting Activin E, a key factor in cardiometabolic disorders and obesity, using iBio's Machine ...
iBio Inc. stock rises Tuesday, outperforms market
Shares of iBio Inc. IBIO rose 3.18% to $2.92 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index COMP rising 0.64% to 19,756.78 ...
manilatimes21d
iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio
Building on the success of the anti-Myostatin program, iBio Launches New Program Featuring Myostatin + Activin A Bispecific Antibody Designed to Promote Weight Loss, Prevent Muscle Loss and Weight ...
Wall Street Journal1y
iBio Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...